Chiasma, Inc.
Chiasma, Inc. CHMA Peers
See (CHMA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CHMA | $3.76 | -6.00% | 0 | -2.39 | -$1.57 | N/A |
| VRTX | $441.30 | -0.47% | 113.3B | -114.92 | -$3.84 | N/A |
| REGN | $521.00 | +0.00% | 55.3B | 13.24 | $39.35 | +0.17% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $322.83 | +1.44% | 42.1B | -153.00 | -$2.11 | N/A |
| ARGX | $560.14 | +0.02% | 34.2B | 34.18 | $16.39 | N/A |
| BNTX | $106.72 | +0.55% | 25.7B | -29.16 | -$3.66 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| RPRX | $35.87 | +1.70% | 20.2B | 14.64 | $2.45 | +2.42% |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
CHMA vs VRTX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, VRTX has a market cap of 113.3B. Regarding current trading prices, CHMA is priced at $3.76, while VRTX trades at $441.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas VRTX's P/E ratio is -114.92. In terms of profitability, CHMA's ROE is -0.84%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, CHMA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs REGN Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, REGN has a market cap of 55.3B. Regarding current trading prices, CHMA is priced at $3.76, while REGN trades at $521.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas REGN's P/E ratio is 13.24. In terms of profitability, CHMA's ROE is -0.84%, compared to REGN's ROE of +0.15%. Regarding short-term risk, CHMA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs SGEN Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CHMA is priced at $3.76, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CHMA's ROE is -0.84%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CHMA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs ALNY Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, ALNY has a market cap of 42.1B. Regarding current trading prices, CHMA is priced at $3.76, while ALNY trades at $322.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas ALNY's P/E ratio is -153.00. In terms of profitability, CHMA's ROE is -0.84%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, CHMA is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs ARGX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, ARGX has a market cap of 34.2B. Regarding current trading prices, CHMA is priced at $3.76, while ARGX trades at $560.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas ARGX's P/E ratio is 34.18. In terms of profitability, CHMA's ROE is -0.84%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, CHMA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs BNTX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, BNTX has a market cap of 25.7B. Regarding current trading prices, CHMA is priced at $3.76, while BNTX trades at $106.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas BNTX's P/E ratio is -29.16. In terms of profitability, CHMA's ROE is -0.84%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, CHMA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs BGNE Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CHMA is priced at $3.76, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CHMA's ROE is -0.84%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, CHMA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs RPRX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, RPRX has a market cap of 20.2B. Regarding current trading prices, CHMA is priced at $3.76, while RPRX trades at $35.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas RPRX's P/E ratio is 14.64. In terms of profitability, CHMA's ROE is -0.84%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, CHMA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs DNA-WT Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CHMA is priced at $3.76, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CHMA's ROE is -0.84%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, CHMA is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs SMMT Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, SMMT has a market cap of 15.3B. Regarding current trading prices, CHMA is priced at $3.76, while SMMT trades at $20.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas SMMT's P/E ratio is -60.68. In terms of profitability, CHMA's ROE is -0.84%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, CHMA is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs INCY Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, INCY has a market cap of 13.2B. Regarding current trading prices, CHMA is priced at $3.76, while INCY trades at $68.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas INCY's P/E ratio is 341.85. In terms of profitability, CHMA's ROE is -0.84%, compared to INCY's ROE of +0.01%. Regarding short-term risk, CHMA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs UTHR Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, UTHR has a market cap of 12.8B. Regarding current trading prices, CHMA is priced at $3.76, while UTHR trades at $284.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas UTHR's P/E ratio is 11.33. In terms of profitability, CHMA's ROE is -0.84%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CHMA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs GMAB Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, GMAB has a market cap of 12.7B. Regarding current trading prices, CHMA is priced at $3.76, while GMAB trades at $20.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas GMAB's P/E ratio is 12.06. In terms of profitability, CHMA's ROE is -0.84%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, CHMA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs KRTX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CHMA is priced at $3.76, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CHMA's ROE is -0.84%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CHMA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs EXEL Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, EXEL has a market cap of 11.9B. Regarding current trading prices, CHMA is priced at $3.76, while EXEL trades at $43.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas EXEL's P/E ratio is 19.94. In terms of profitability, CHMA's ROE is -0.84%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, CHMA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs BMRN Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, CHMA is priced at $3.76, while BMRN trades at $55.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas BMRN's P/E ratio is 20.43. In terms of profitability, CHMA's ROE is -0.84%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, CHMA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs MRNA Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, MRNA has a market cap of 10.5B. Regarding current trading prices, CHMA is priced at $3.76, while MRNA trades at $27.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas MRNA's P/E ratio is -3.11. In terms of profitability, CHMA's ROE is -0.84%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, CHMA is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs ASND Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, ASND has a market cap of 10.4B. Regarding current trading prices, CHMA is priced at $3.76, while ASND trades at $172.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas ASND's P/E ratio is -25.83. In terms of profitability, CHMA's ROE is -0.84%, compared to ASND's ROE of +1.91%. Regarding short-term risk, CHMA is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs RXDX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CHMA is priced at $3.76, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CHMA's ROE is -0.84%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CHMA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs IMGN Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CHMA is priced at $3.76, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CHMA's ROE is -0.84%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, CHMA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs BBIO Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, BBIO has a market cap of 8.5B. Regarding current trading prices, CHMA is priced at $3.76, while BBIO trades at $44.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas BBIO's P/E ratio is -12.60. In terms of profitability, CHMA's ROE is -0.84%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, CHMA is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs BPMC Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, BPMC has a market cap of 8.3B. Regarding current trading prices, CHMA is priced at $3.76, while BPMC trades at $128.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas BPMC's P/E ratio is -51.24. In terms of profitability, CHMA's ROE is -0.84%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, CHMA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs CERE Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CHMA is priced at $3.76, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas CERE's P/E ratio is -16.47. In terms of profitability, CHMA's ROE is -0.84%, compared to CERE's ROE of -0.43%. Regarding short-term risk, CHMA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs TECH Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, TECH has a market cap of 8.1B. Regarding current trading prices, CHMA is priced at $3.76, while TECH trades at $51.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas TECH's P/E ratio is 62.46. In terms of profitability, CHMA's ROE is -0.84%, compared to TECH's ROE of +0.06%. Regarding short-term risk, CHMA is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs VRNA Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, VRNA has a market cap of 8B. Regarding current trading prices, CHMA is priced at $3.76, while VRNA trades at $93.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas VRNA's P/E ratio is -46.91. In terms of profitability, CHMA's ROE is -0.84%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, CHMA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs ROIVW Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, CHMA is priced at $3.76, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, CHMA's ROE is -0.84%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, CHMA is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs CORT Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, CORT has a market cap of 7.8B. Regarding current trading prices, CHMA is priced at $3.76, while CORT trades at $73.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas CORT's P/E ratio is 63.67. In terms of profitability, CHMA's ROE is -0.84%, compared to CORT's ROE of +0.20%. Regarding short-term risk, CHMA is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs ROIV Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, ROIV has a market cap of 7.7B. Regarding current trading prices, CHMA is priced at $3.76, while ROIV trades at $11.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas ROIV's P/E ratio is -15.19. In terms of profitability, CHMA's ROE is -0.84%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, CHMA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs RVMD Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, RVMD has a market cap of 6.9B. Regarding current trading prices, CHMA is priced at $3.76, while RVMD trades at $36.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas RVMD's P/E ratio is -9.20. In terms of profitability, CHMA's ROE is -0.84%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, CHMA is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs MDGL Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, MDGL has a market cap of 6.7B. Regarding current trading prices, CHMA is priced at $3.76, while MDGL trades at $300.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas MDGL's P/E ratio is -16.87. In terms of profitability, CHMA's ROE is -0.84%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, CHMA is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs RETA Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CHMA is priced at $3.76, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas RETA's P/E ratio is -66.29. In terms of profitability, CHMA's ROE is -0.84%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CHMA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs AMRN Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, AMRN has a market cap of 6.5B. Regarding current trading prices, CHMA is priced at $3.76, while AMRN trades at $15.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas AMRN's P/E ratio is -3.57. In terms of profitability, CHMA's ROE is -0.84%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, CHMA is more volatile compared to AMRN. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs JAZZ Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, JAZZ has a market cap of 6.5B. Regarding current trading prices, CHMA is priced at $3.76, while JAZZ trades at $106.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas JAZZ's P/E ratio is 14.52. In terms of profitability, CHMA's ROE is -0.84%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, CHMA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs HALO Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, HALO has a market cap of 6.4B. Regarding current trading prices, CHMA is priced at $3.76, while HALO trades at $52.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas HALO's P/E ratio is 13.89. In terms of profitability, CHMA's ROE is -0.84%, compared to HALO's ROE of +1.22%. Regarding short-term risk, CHMA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs IONS Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, IONS has a market cap of 6.3B. Regarding current trading prices, CHMA is priced at $3.76, while IONS trades at $39.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas IONS's P/E ratio is -13.31. In terms of profitability, CHMA's ROE is -0.84%, compared to IONS's ROE of -0.92%. Regarding short-term risk, CHMA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs TGTX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, TGTX has a market cap of 5.8B. Regarding current trading prices, CHMA is priced at $3.76, while TGTX trades at $36.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas TGTX's P/E ratio is 146.88. In terms of profitability, CHMA's ROE is -0.84%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, CHMA is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs ABCM Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CHMA is priced at $3.76, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CHMA's ROE is -0.84%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CHMA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs ISEE Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CHMA is priced at $3.76, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CHMA's ROE is -0.84%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CHMA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs TLX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, TLX has a market cap of 5.4B. Regarding current trading prices, CHMA is priced at $3.76, while TLX trades at $16.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas TLX's P/E ratio is 177.67. In terms of profitability, CHMA's ROE is -0.84%, compared to TLX's ROE of +0.14%. Regarding short-term risk, CHMA is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs NUVL Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, NUVL has a market cap of 5.3B. Regarding current trading prices, CHMA is priced at $3.76, while NUVL trades at $79.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas NUVL's P/E ratio is -18.03. In terms of profitability, CHMA's ROE is -0.84%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, CHMA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs AXSM Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, AXSM has a market cap of 5.1B. Regarding current trading prices, CHMA is priced at $3.76, while AXSM trades at $103.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas AXSM's P/E ratio is -17.91. In terms of profitability, CHMA's ROE is -0.84%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, CHMA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs ALKS Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, CHMA is priced at $3.76, while ALKS trades at $28.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas ALKS's P/E ratio is 13.72. In terms of profitability, CHMA's ROE is -0.84%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, CHMA is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs AKRO Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, CHMA is priced at $3.76, while AKRO trades at $56.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas AKRO's P/E ratio is -14.98. In terms of profitability, CHMA's ROE is -0.84%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, CHMA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs ALPN Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CHMA is priced at $3.76, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CHMA's ROE is -0.84%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, CHMA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs ADMA Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, ADMA has a market cap of 4.3B. Regarding current trading prices, CHMA is priced at $3.76, while ADMA trades at $18.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas ADMA's P/E ratio is 21.62. In terms of profitability, CHMA's ROE is -0.84%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, CHMA is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs PCVX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, PCVX has a market cap of 4.2B. Regarding current trading prices, CHMA is priced at $3.76, while PCVX trades at $32.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas PCVX's P/E ratio is -8.17. In terms of profitability, CHMA's ROE is -0.84%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, CHMA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs OPT Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CHMA is priced at $3.76, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas OPT's P/E ratio is -1.52. In terms of profitability, CHMA's ROE is -0.84%, compared to OPT's ROE of +2.60%. Regarding short-term risk, CHMA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs SLNO Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, SLNO has a market cap of 4.2B. Regarding current trading prices, CHMA is priced at $3.76, while SLNO trades at $83.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas SLNO's P/E ratio is -17.56. In terms of profitability, CHMA's ROE is -0.84%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, CHMA is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs MRTX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CHMA is priced at $3.76, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CHMA's ROE is -0.84%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CHMA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs CRSP Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, CRSP has a market cap of 4.1B. Regarding current trading prices, CHMA is priced at $3.76, while CRSP trades at $47.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas CRSP's P/E ratio is -10.58. In terms of profitability, CHMA's ROE is -0.84%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, CHMA is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs KRYS Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, KRYS has a market cap of 4B. Regarding current trading prices, CHMA is priced at $3.76, while KRYS trades at $138.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas KRYS's P/E ratio is 33.30. In terms of profitability, CHMA's ROE is -0.84%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, CHMA is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs RYTM Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, RYTM has a market cap of 4B. Regarding current trading prices, CHMA is priced at $3.76, while RYTM trades at $62.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas RYTM's P/E ratio is -22.40. In terms of profitability, CHMA's ROE is -0.84%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, CHMA is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs CYTK Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, CYTK has a market cap of 4B. Regarding current trading prices, CHMA is priced at $3.76, while CYTK trades at $33.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas CYTK's P/E ratio is -6.27. In terms of profitability, CHMA's ROE is -0.84%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, CHMA is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs PTCT Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, PTCT has a market cap of 4B. Regarding current trading prices, CHMA is priced at $3.76, while PTCT trades at $49.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas PTCT's P/E ratio is 7.66. In terms of profitability, CHMA's ROE is -0.84%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, CHMA is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs MRUS Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, MRUS has a market cap of 3.9B. Regarding current trading prices, CHMA is priced at $3.76, while MRUS trades at $52.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas MRUS's P/E ratio is -12.72. In terms of profitability, CHMA's ROE is -0.84%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, CHMA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs ZLAB Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, ZLAB has a market cap of 3.8B. Regarding current trading prices, CHMA is priced at $3.76, while ZLAB trades at $34.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas ZLAB's P/E ratio is -13.90. In terms of profitability, CHMA's ROE is -0.84%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, CHMA is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs RYZB Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CHMA is priced at $3.76, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CHMA's ROE is -0.84%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CHMA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs CBAY Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CHMA is priced at $3.76, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CHMA's ROE is -0.84%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CHMA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs ACAD Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, CHMA is priced at $3.76, while ACAD trades at $22.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas ACAD's P/E ratio is 16.15. In terms of profitability, CHMA's ROE is -0.84%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, CHMA is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs ACLX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, ACLX has a market cap of 3.6B. Regarding current trading prices, CHMA is priced at $3.76, while ACLX trades at $65.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas ACLX's P/E ratio is -21.86. In terms of profitability, CHMA's ROE is -0.84%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, CHMA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs SWTX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, CHMA is priced at $3.76, while SWTX trades at $46.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas SWTX's P/E ratio is -13.78. In terms of profitability, CHMA's ROE is -0.84%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, CHMA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs RNA Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, RNA has a market cap of 3.5B. Regarding current trading prices, CHMA is priced at $3.76, while RNA trades at $29.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas RNA's P/E ratio is -9.68. In terms of profitability, CHMA's ROE is -0.84%, compared to RNA's ROE of -0.27%. Regarding short-term risk, CHMA is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs RARE Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, RARE has a market cap of 3.5B. Regarding current trading prices, CHMA is priced at $3.76, while RARE trades at $36.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas RARE's P/E ratio is -6.26. In terms of profitability, CHMA's ROE is -0.84%, compared to RARE's ROE of -1.86%. Regarding short-term risk, CHMA is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs PTGX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, PTGX has a market cap of 3.5B. Regarding current trading prices, CHMA is priced at $3.76, while PTGX trades at $55.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas PTGX's P/E ratio is 71.40. In terms of profitability, CHMA's ROE is -0.84%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, CHMA is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs AAPG Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, AAPG has a market cap of 3.4B. Regarding current trading prices, CHMA is priced at $3.76, while AAPG trades at $39.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas AAPG's P/E ratio is -52.80. In terms of profitability, CHMA's ROE is -0.84%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, CHMA is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs SRRK Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, SRRK has a market cap of 3.4B. Regarding current trading prices, CHMA is priced at $3.76, while SRRK trades at $35.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas SRRK's P/E ratio is -14.04. In terms of profitability, CHMA's ROE is -0.84%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, CHMA is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs LEGN Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, LEGN has a market cap of 3.2B. Regarding current trading prices, CHMA is priced at $3.76, while LEGN trades at $34.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas LEGN's P/E ratio is -29.35. In terms of profitability, CHMA's ROE is -0.84%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, CHMA is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs MLTX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, MLTX has a market cap of 3B. Regarding current trading prices, CHMA is priced at $3.76, while MLTX trades at $47.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas MLTX's P/E ratio is -20.69. In terms of profitability, CHMA's ROE is -0.84%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, CHMA is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs MTSR Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, MTSR has a market cap of 3B. Regarding current trading prices, CHMA is priced at $3.76, while MTSR trades at $28.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas MTSR's P/E ratio is -11.26. In terms of profitability, CHMA's ROE is -0.84%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, CHMA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs VKTX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, VKTX has a market cap of 3B. Regarding current trading prices, CHMA is priced at $3.76, while VKTX trades at $26.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas VKTX's P/E ratio is -22.86. In terms of profitability, CHMA's ROE is -0.84%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, CHMA is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs KYMR Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, KYMR has a market cap of 2.9B. Regarding current trading prices, CHMA is priced at $3.76, while KYMR trades at $44.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas KYMR's P/E ratio is -14.19. In terms of profitability, CHMA's ROE is -0.84%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, CHMA is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs MORF Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, CHMA is priced at $3.76, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas MORF's P/E ratio is -14.88. In terms of profitability, CHMA's ROE is -0.84%, compared to MORF's ROE of -0.22%. Regarding short-term risk, CHMA is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs MOR Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, CHMA is priced at $3.76, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas MOR's P/E ratio is -12.64. In terms of profitability, CHMA's ROE is -0.84%, compared to MOR's ROE of +2.51%. Regarding short-term risk, CHMA is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs CRNX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, CRNX has a market cap of 2.8B. Regarding current trading prices, CHMA is priced at $3.76, while CRNX trades at $29.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas CRNX's P/E ratio is -7.92. In terms of profitability, CHMA's ROE is -0.84%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, CHMA is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs IMVT Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, IMVT has a market cap of 2.8B. Regarding current trading prices, CHMA is priced at $3.76, while IMVT trades at $16.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas IMVT's P/E ratio is -5.90. In terms of profitability, CHMA's ROE is -0.84%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, CHMA is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs KDNY Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, CHMA is priced at $3.76, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas KDNY's P/E ratio is -12.47. In terms of profitability, CHMA's ROE is -0.84%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, CHMA is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs CPRX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, CPRX has a market cap of 2.7B. Regarding current trading prices, CHMA is priced at $3.76, while CPRX trades at $21.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas CPRX's P/E ratio is 13.87. In terms of profitability, CHMA's ROE is -0.84%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, CHMA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs MYOV Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, CHMA is priced at $3.76, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas MYOV's P/E ratio is -14.05. In terms of profitability, CHMA's ROE is -0.84%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, CHMA is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs APGE Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, APGE has a market cap of 2.6B. Regarding current trading prices, CHMA is priced at $3.76, while APGE trades at $43.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas APGE's P/E ratio is -12.02. In terms of profitability, CHMA's ROE is -0.84%, compared to APGE's ROE of -0.19%. Regarding short-term risk, CHMA is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs MIRM Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, MIRM has a market cap of 2.5B. Regarding current trading prices, CHMA is priced at $3.76, while MIRM trades at $51.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas MIRM's P/E ratio is -31.73. In terms of profitability, CHMA's ROE is -0.84%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, CHMA is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs XENE Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, XENE has a market cap of 2.5B. Regarding current trading prices, CHMA is priced at $3.76, while XENE trades at $32.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas XENE's P/E ratio is -10.06. In terms of profitability, CHMA's ROE is -0.84%, compared to XENE's ROE of -0.32%. Regarding short-term risk, CHMA is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs IBRX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, IBRX has a market cap of 2.4B. Regarding current trading prices, CHMA is priced at $3.76, while IBRX trades at $2.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas IBRX's P/E ratio is -4.74. In terms of profitability, CHMA's ROE is -0.84%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, CHMA is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs PRVB Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, CHMA is priced at $3.76, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas PRVB's P/E ratio is -16.43. In terms of profitability, CHMA's ROE is -0.84%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, CHMA is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs LBPH Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, CHMA is priced at $3.76, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas LBPH's P/E ratio is -26.66. In terms of profitability, CHMA's ROE is -0.84%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, CHMA is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs DICE Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, CHMA is priced at $3.76, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas DICE's P/E ratio is -21.91. In terms of profitability, CHMA's ROE is -0.84%, compared to DICE's ROE of +0.56%. Regarding short-term risk, CHMA is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs ARWR Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, ARWR has a market cap of 2.2B. Regarding current trading prices, CHMA is priced at $3.76, while ARWR trades at $16.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas ARWR's P/E ratio is -12.97. In terms of profitability, CHMA's ROE is -0.84%, compared to ARWR's ROE of -0.47%. Regarding short-term risk, CHMA is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs LGND Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, LGND has a market cap of 2.2B. Regarding current trading prices, CHMA is priced at $3.76, while LGND trades at $114.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas LGND's P/E ratio is -15.66. In terms of profitability, CHMA's ROE is -0.84%, compared to LGND's ROE of -0.16%. Regarding short-term risk, CHMA is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs APLS Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, APLS has a market cap of 2.2B. Regarding current trading prices, CHMA is priced at $3.76, while APLS trades at $17.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas APLS's P/E ratio is -9.68. In terms of profitability, CHMA's ROE is -0.84%, compared to APLS's ROE of -1.00%. Regarding short-term risk, CHMA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs CALT Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, CHMA is priced at $3.76, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas CALT's P/E ratio is -22.73. In terms of profitability, CHMA's ROE is -0.84%, compared to CALT's ROE of -1.67%. Regarding short-term risk, CHMA is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs VCYT Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, VCYT has a market cap of 2.1B. Regarding current trading prices, CHMA is priced at $3.76, while VCYT trades at $27.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas VCYT's P/E ratio is 65.19. In terms of profitability, CHMA's ROE is -0.84%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, CHMA is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs VCEL Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, CHMA is priced at $3.76, while VCEL trades at $41.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas VCEL's P/E ratio is 834.60. In terms of profitability, CHMA's ROE is -0.84%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, CHMA is more volatile compared to VCEL. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs NAMS Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, NAMS has a market cap of 2.1B. Regarding current trading prices, CHMA is priced at $3.76, while NAMS trades at $18.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas NAMS's P/E ratio is -10.09. In terms of profitability, CHMA's ROE is -0.84%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, CHMA is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs DNLI Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, DNLI has a market cap of 2B. Regarding current trading prices, CHMA is priced at $3.76, while DNLI trades at $14.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas DNLI's P/E ratio is -5.28. In terms of profitability, CHMA's ROE is -0.84%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, CHMA is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs KNSA Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, KNSA has a market cap of 2B. Regarding current trading prices, CHMA is priced at $3.76, while KNSA trades at $28.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas KNSA's P/E ratio is -116.83. In terms of profitability, CHMA's ROE is -0.84%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, CHMA is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs RXRX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, RXRX has a market cap of 2B. Regarding current trading prices, CHMA is priced at $3.76, while RXRX trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas RXRX's P/E ratio is -2.79. In terms of profitability, CHMA's ROE is -0.84%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, CHMA is less volatile compared to RXRX. This indicates potentially lower risk in terms of short-term price fluctuations for CHMA.
CHMA vs CGON Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, CGON has a market cap of 2B. Regarding current trading prices, CHMA is priced at $3.76, while CGON trades at $25.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas CGON's P/E ratio is -17.30. In terms of profitability, CHMA's ROE is -0.84%, compared to CGON's ROE of -0.17%. Regarding short-term risk, CHMA is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs BCRX Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, BCRX has a market cap of 2B. Regarding current trading prices, CHMA is priced at $3.76, while BCRX trades at $9.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas BCRX's P/E ratio is -36.00. In terms of profitability, CHMA's ROE is -0.84%, compared to BCRX's ROE of +0.11%. Regarding short-term risk, CHMA is less volatile compared to BCRX. This indicates potentially lower risk in terms of short-term price fluctuations for CHMA.
CHMA vs AGIO Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, AGIO has a market cap of 1.9B. Regarding current trading prices, CHMA is priced at $3.76, while AGIO trades at $33.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas AGIO's P/E ratio is 2.90. In terms of profitability, CHMA's ROE is -0.84%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, CHMA is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.
CHMA vs BLTE Comparison
CHMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHMA stands at 0. In comparison, BLTE has a market cap of 1.9B. Regarding current trading prices, CHMA is priced at $3.76, while BLTE trades at $59.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHMA currently has a P/E ratio of -2.39, whereas BLTE's P/E ratio is -43.41. In terms of profitability, CHMA's ROE is -0.84%, compared to BLTE's ROE of -0.32%. Regarding short-term risk, CHMA is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for CHMA.